×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NUVL – nuvalent, inc. - class a (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NUVL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/21
10:48 am
nuvl
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
Low
Report
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]
4/21
10:32 am
nuvl
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Low
Report
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
4/21
08:14 am
nuvl
Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
Low
Report
Nuvalent (NUVL) had its "buy" rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
4/17
04:54 pm
nuvl
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]
Low
Report
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026 [Yahoo! Finance]
4/17
04:01 pm
nuvl
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Low
Report
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
4/8
08:49 am
nuvl
Nuvalent (NUVL) had its "outperform" rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
Low
Report
Nuvalent (NUVL) had its "outperform" rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
4/7
06:30 am
nuvl
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
Low
Report
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
3/30
08:43 am
nuvl
Nuvalent (NUVL) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $116.00 price target on the stock.
Low
Report
Nuvalent (NUVL) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $116.00 price target on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/13
04:30 pm
nuvl
Form 4 Nuvalent, Inc. For: Apr 09 Filed by: Pelish Henry E.
Low
Report
Form 4 Nuvalent, Inc. For: Apr 09 Filed by: Pelish Henry E.
4/8
04:30 pm
nuvl
Form 4 Nuvalent, Inc. For: Apr 06 Filed by: Porter James Richard
Low
Report
Form 4 Nuvalent, Inc. For: Apr 06 Filed by: Porter James Richard
4/7
06:33 am
nuvl
Form 8-K Nuvalent, Inc. For: Apr 07
Low
Report
Form 8-K Nuvalent, Inc. For: Apr 07
4/3
04:30 pm
nuvl
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Balcom Alexandra
Low
Report
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Balcom Alexandra
4/2
04:30 pm
nuvl
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Lane Benjamin
Low
Report
Form 4 Nuvalent, Inc. For: Apr 01 Filed by: Lane Benjamin
4/1
04:31 pm
nuvl
Form 4 Nuvalent, Inc. For: Mar 30 Filed by: Noci Darlene
Low
Report
Form 4 Nuvalent, Inc. For: Mar 30 Filed by: Noci Darlene
3/30
05:59 pm
nuvl
Form 144 Nuvalent, Inc. Filed by: Noci Darlene
Medium
Report
Form 144 Nuvalent, Inc. Filed by: Noci Darlene
3/30
05:34 pm
nuvl
Form 4 Nuvalent, Inc. For: Mar 26 Filed by: Miller Deborah Ann
Medium
Report
Form 4 Nuvalent, Inc. For: Mar 26 Filed by: Miller Deborah Ann
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: